Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Benzodiazepine or Tryptamine or [[:Category:Tryptamines|Tryptamine]]

Use the filters below to narrow your results.

generic:
brand:
None (36) · COMP360 (Compass Pathways, investigational synthesized clinical formulation) (1) · Dalmane (1) · Doral (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (15) · 5-HT2A agonist; 5-HT3 antagonist (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · 5-HT2A partial agonist; sigma-1 agonist (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of psilocin; 5-HT2A agonist (1) · Prodrug to [[Psilocin|psilocin]] (4-hydroxy-N,N-dimethyltryptamine), a partial agonist at the [[Receptor:5-HT2A|5-HT2A]] serotonin receptor; the action that defines the classical-psychedelic mechanism (1)
uses:
None (49) · (investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"' (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
None (49) · 0.25 mg (1) · Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support (1)
preparations:
None (49) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · Synthesized psilocybin capsules (COMP360 and other investigational formulations); dried whole [[Psilocybe|Psilocybe]] mushrooms (variable potency, no legal supply chain in most jurisdictions); psilocybin truffles (Psilocybe sclerotia, legal in the Netherlands) (1)
fda max:
None (49) · 10 mg/d (1) · Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing (1)
routes:
None (49) · Oral (2)
onset:
None (49) · 20-45 min subjective onset; psilocin formation from psilocybin requires intestinal and hepatic alkaline phosphatase (1) · 30-60 min (immediate-release); 1-2 h (extended-release) (1)
duration:
None (48) · 4-6 hours (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · About 20 minutes (1)
halflife:
None (48) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 9–12 minutes (intravenous) (1) · Psilocin: ~2-3 h; psilocybin itself is a prodrug, dephosphorylated within minutes of absorption (1)
bioavailability:
None (49) · 80-90% oral (1) · Oral bioavailability of psilocin from administered psilocybin approximately 50% (1)
pregnancy:
None (49) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Not studied in human pregnancy; no approved clinical use in any population (1)
legal:
None (49) · Schedule IV (US) (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)

Showing below up to 51 results in range #1 to #51.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"